Literature DB >> 6785815

Repeated electroconvulsive shock prevents the sedative effect of small doses of apomorphine.

G Serra, A Argiolas, F Fadda, M R Melis, G L Gessa.   

Abstract

Repeated electroconvulsive shock (ECS) (one shock daily for 8 days), but not single ECS, eliminates the sedative response to small doses of apomorphine (25--1000 microgram/kg) and potentiates the stimulant response to high doses (200 microgram/kg) of the drug in rats. This effect is observed 1 and 4 days after the last ECS. However, repeated ECS does not prevent the inhibitory effect of apomorphine on dopamine (DA) synthesis. The results suggest that repeated ECS may lead to the development of subsensitivity in DA receptors that mediate sedation and that these receptors are differentiated from those controlling DA synthesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785815     DOI: 10.1007/BF00429217

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Effect of electroconvulsive shock on monoaminergic receptor binding sites in rat brain.

Authors:  D A Bergstrom; K J Kellar
Journal:  Nature       Date:  1979-03-29       Impact factor: 49.962

2.  Electroconvulsive shock and postsynaptic catecholamine effects: increased psychomotor stimulant action of apomorphine and clonidine in reserpine pretreated mice by repeated ECS.

Authors:  K Modigh
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

3.  Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine.

Authors:  A R Green; D J Heal; D G Grahame-Smith
Journal:  Psychopharmacology (Berl)       Date:  1977-04-29       Impact factor: 4.530

4.  Behavioral effects of a lesion in the ventral mesencephalic tegmentum: evidence for involvement of A10 dopaminergic neurons.

Authors:  M Le Moal; L Stinus; H Simon; J P Tassin; A M Thierry; G Blanc; J Glowinski; B Cardo
Journal:  Adv Biochem Psychopharmacol       Date:  1977

5.  Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response.

Authors:  R M Post; R H Gerner; J S Carman; J C Gillin; D C Jimerson; F K Goodwin; W E Bunney
Journal:  Arch Gen Psychiatry       Date:  1978-05

6.  Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones.

Authors:  B S Bunney; G K Aghajanian; R H Roth
Journal:  Nat New Biol       Date:  1973-09-26

7.  Mechanism of the antidepressant action of electroconvulsive therapy.

Authors:  D G Grahame-Smith; A R Green; D W Costain
Journal:  Lancet       Date:  1978-02-04       Impact factor: 79.321

8.  Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.

Authors:  R H Roth; L C Murrin; J R Walters
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

9.  A radioenzymatic method to measure picogram amounts of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) in small samples of brain tissue.

Authors:  A Argiolas; F Fadda
Journal:  Experientia       Date:  1978-06-15

10.  Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain.

Authors:  U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

View more
  13 in total

1.  MK-801 prevents the enhanced behavioural response to apomorphine elicited by repeated electroconvulsive treatment in mice.

Authors:  G G Nomikos; A A Mathé; J M Mathé; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effects of chronic electroconvulsive shock on interstitial concentrations of dopamine in the nucleus accumbens.

Authors:  G G Nomikos; A P Zis; G Damsma; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Regional neurotransmitter responses after acute and chronic electroconvulsive shock.

Authors:  P Glue; M J Costello; A Pert; A Mele; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Chlorimipramine, electroconvulsive shock and combination thereof: differential effects of chronic treatment on apomorphine-induced behaviours and on striatal and mesocortical dopamine turnover.

Authors:  C Spyraki; Z Papadopoulou; A Kourkoubas; D Varonos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

5.  In vivo neurochemical effects of electroconvulsive shock studied by microdialysis in the rat striatum.

Authors:  A P Zis; G G Nomikos; G Damsma; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.

Authors:  A Reches; H R Wagner; A I Barkai; V Jackson; E Yablonskaya-Alter; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Dopamine and serotonin metabolites in rat cerebroventricular fluid following withdrawal of haloperidol or electroshock treatment.

Authors:  A I Barkai; S Kowalik; A Reches
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression.

Authors:  A Vaccheri; R Dall'Olio; R Gaggi; O Gandolfi; N Montanaro
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram.

Authors:  J Arnt; K F Overø; J Hyttel; R Olsen
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Time course of rat motility response to apomorphine: a simple model for studying preferential blockade of brain dopamine receptors mediating sedation.

Authors:  N Montanaro; A Vaccheri; R Dall'Olio; O Gandolfi
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.